Skip to main content

GeneBio and Current Science Group Form JV to Launch Protein Database

NEW YORK, March 3 (GenomeWeb News) - Geneva Bioinformatics and the Current Science Group, a London-based publishing group, have formed a joint venture company to develop and market a web-based protein information resource, the companies said today.

 

The new company, called Current BioData, will develop, promote, and distribute ProXenter, a protein database product developed by GeneBio over the last three years.

 

ProXenter focuses on specific groups of proteins of high interest to life sciences research, particularly the pharmaceutical industry. It consists of a protein relational database that holds a comprehensive dataset for each known protein in a specific group. This includes data from major databases, such as Swiss-Prot, manual annotation by experts, and pre-computed protein properties. ProXenter also offers a number of bioinformatics tools, as well as browsing, visualization, and analysis tools.

 

Current BioData and the Swiss-Prot Group at the Swiss Institute of Bioinformatics plan to collaborate to keep the product updated.

 

The first version of ProXenter will be launched "very soon," according to the companies.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.